Definition of bulky disease in early stage hodgkin lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes

Haematologica

Volumn 101, Issue 10, 2016, Pages 1237-1243

  Kumar, Anita ^a   Burger, Irene A ^b   Zhang, Zhigang ^a   Drill, Esther N ^a   Migliacci, Jocelyn C ^a   Ng, Andrea ^c   Lacasce, Ann ^d   Wall, Darci ^e   Witzig, Thomas E ^e   Ristow, Kay ^e   Yahalom, Joachim ^a   Moskowitz, Craig H ^a   Zelenetz, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; RITUXIMAB; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMAGE RECONSTRUCTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; VALIDATION PROCESS; COHORT ANALYSIS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOTHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84989352657     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.141846     Document Type: Article

References (27)

1. Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer. 1978;42(3):1039-1045.
2. Schomberg PJ, Evans RG, O'Connell MJ, et al. Prognostic significance of mediastinal mass in adult Hodgkin's disease. Cancer. 1984;53(2):324-328.
3. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-1636.
4. Eghbali H, Raemaekers J, Carde P, Group EL. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol. 2005;(Suppl):135-40.
5. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601-3608.
6. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634-4642.
7. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(5):589-597.
8. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
9. Mendenhall NP, Cantor AB, Barre DM, Lynch JW Jr, Million RR. The role of prognostic factors in treatment selection for early-stage Hodgkin's disease. Am J Clin Oncol. 1994;17(3):189-195.
10. North LB, Fuller LM, Hagemeister FB, Rodgers RW, Butler JJ, Shullenberger CC. Importance of initial mediastinal adenopathy in Hodgkin disease. Am J Roentgenology. 1982;138(2):229-235.
11. Bradley AJ, Carrington BM, Lawrance JA, Ryder WD, Radford JA. Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. J Clin Oncol. 1999;17(8):2493-2498.
12. Radford J, Illidge T, Counsell N, et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma. N Engl J Med. 2015;372(17):1598-1607.
13. Straus D, Pitcher BN, Kostakoglu L, al. E. Initial Results of US Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky Stage I and II Hodgkin lymphoma (HL) (CALGB/Alliance 50604). ASH Annual Meeting Abstracts. Blood. 2015;126(23):578.
14. Rosset A, Spadola L, Pysher L, Ratib O. Informatics in radiology (infoRAD): navigating the fifth dimension: innovative interface for multidimensional multimodality image navigation. Radiographics. 2006; 26(1):299-308.
15. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 2000;19(1):113-132.
16. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92(4):965-970.
17. Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070-6.
18. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48(9):1721-1727.
19. Sandrasegaran K, Rydberg J, Tann M, Hawes DR, Kopecky KK, Maglinte DD. Benefits of routine use of coronal and sagittal reformations in multi-slice CT examination of the abdomen and pelvis. Clin Radiol. 2007;62(4):340-347.
20. Wei SC, Ulmer S, Lev MH, Pomerantz SR, Gonzalez RG, Henson JW. Value of coronal reformations in the CT evaluation of acute head trauma. Am J Neuroradiol. 2010; 31(2):334-339.
21. Behar RA, Horning SJ, Hoppe RT. Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy. Int J Radiat Oncol Biol Phys. 1993;25(5):771-776.
22. Hughes-Davies L, Tarbell NJ, Coleman CN, et al. Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys. 1997;39(2):361-369.
23. Leopold KA, Canellos GP, Rosenthal D, Shulman LN, Weinstein H, Mauch P. Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol. 1989;7(8):1059-1065.
24. Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188-1194.
25. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
26. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483-3489.
27. Savage KJ, Connors JM, Villa DR, al. E. Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation Blood (ASH Annual Meeting Abstracts). 2015;126.